Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic ... - Business Wire (press release)

Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic ...Business Wire (press release)... were published online today by The Journal of the American Medical Association (JAMA). Fremanezumab is a monoclonal antibody that selectively targets CGRP (calcitonin gene-related peptide), a neuropeptide involved in the pathophysiology of migraine.and more »